ChromaDex (NASDAQ:CDXC) Stock Passes Above Two Hundred Day Moving Average – Time to Sell?

ChromaDex Co. (NASDAQ:CDXCGet Free Report) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $4.22 and traded as high as $5.55. ChromaDex shares last traded at $5.30, with a volume of 256,732 shares changing hands.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Roth Mkm boosted their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. StockNews.com raised shares of ChromaDex from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 25th. Finally, HC Wainwright lifted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, November 4th.

Check Out Our Latest Research Report on ChromaDex

ChromaDex Stock Performance

The business’s 50 day moving average is $6.25 and its 200 day moving average is $4.23. The stock has a market cap of $420.87 million, a price-to-earnings ratio of 551.55 and a beta of 2.15.

ChromaDex (NASDAQ:CDXCGet Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The firm had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. During the same period in the prior year, the business earned ($0.01) EPS. Research analysts expect that ChromaDex Co. will post 0.04 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the transaction, the director now owns 244,179 shares in the company, valued at approximately $1,511,468.01. This trade represents a 13.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 9.64% of the company’s stock.

Hedge Funds Weigh In On ChromaDex

Several institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in shares of ChromaDex by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock valued at $4,197,000 after acquiring an additional 17,963 shares during the last quarter. State Street Corp boosted its position in ChromaDex by 11.3% during the third quarter. State Street Corp now owns 618,028 shares of the company’s stock worth $2,256,000 after purchasing an additional 62,692 shares during the period. Renaissance Technologies LLC raised its stake in shares of ChromaDex by 8.4% in the second quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after acquiring an additional 32,400 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of ChromaDex by 11.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock worth $1,211,000 after acquiring an additional 33,150 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new stake in ChromaDex during the 2nd quarter worth approximately $597,000. 15.41% of the stock is currently owned by institutional investors.

ChromaDex Company Profile

(Get Free Report)

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

See Also

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.